Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm

Cancer Family

Nervous System Neoplasm

CI-CAN-00000038Explore in graph →

Non-malignant1,523 active trials9 approved drugs210 evidence items

NCIt: C3268
MeSH: D009423

Overview
Statistics
Survival
Genomics48
Variants & evidence210
Drugs47
Trials5871
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Germline mutations in the vhl gene in patients presenting with phaeochromocytomas.
· Int J Cancer · 1998 · PMID 9663592 · validated civic_curation pubmed
Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family?
· Cancer Genet Cytogenet · 2010 · PMID 20193854 · validated civic_curation pubmed
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
· J Neurosurg Spine · 2011 · PMID 21294614 · validated civic_curation pubmed
CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma.
· Neuropathol Appl Neurobiol · 2019 · PMID 29804288 · validated civic_curation pubmed
Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
· Acta Neuropathol Commun · 2021 · PMID 34389065 · validated civic_curation pubmed
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.
· Acta Neuropathol · 2010 · PMID 21046410 · validated civic_curation pubmed
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

Showing 101–125 of 168 publications

← Previous
1
…
4
5
6
7
Next →

Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation.

· J Neuropathol Exp Neurol · 2021 · PMID 34363682 · validated civic_curation pubmed

Supratentorial ependymoma with YAP1:FAM118B fusion: A case report.

· Neuropathology · 2021 · PMID 33480048 · validated civic_curation pubmed

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma.

· Neurooncol Adv · 2022 · PMID 35673607 · validated civic_curation pubmed

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

· Nature · 2008 · PMID 18923525 · validated civic_curation pubmed

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

· Science · 2013 · PMID 23558169 · validated civic_curation pubmed

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

· Cancer Discov · 2016 · PMID 26554404 · validated civic_curation pubmed

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

· Sci Transl Med · 2016 · PMID 26936505 · validated civic_curation pubmed

A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.

· Cell Rep · 2018 · PMID 29949764 · validated civic_curation pubmed

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

· Cancer Cell · 2011 · PMID 21575866 · validated civic_curation pubmed

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

· Clin Cancer Res · 2011 · PMID 21948233 · validated civic_curation pubmed

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

· Sci Transl Med · 2011 · PMID 22072639 · validated civic_curation pubmed

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

· Mol Cancer Ther · 2013 · PMID 23960094 · validated civic_curation pubmed

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

· Sci Transl Med · 2015 · PMID 26537256 · validated civic_curation pubmed

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

· PLoS One · 2016 · PMID 26821351 · validated civic_curation pubmed

Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.

· Proc Natl Acad Sci U S A · 2012 · PMID 22550175 · validated civic_curation pubmed

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

· Sci Rep · 2016 · PMID 26786851 · validated civic_curation pubmed

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.

· Oncotarget · 2016 · PMID 27049722 · validated civic_curation pubmed

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

· Cancer Res · 2010 · PMID 20354191 · validated civic_curation pubmed